Cancer on motors: How kinesins drive prostate cancer progression?
Biochemical Pharmacology · 2024-06 · 224 · 116229
DOI: 10.1016/j.bcp.2024.116229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2024-06. Verfasst von Jia-Ming Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Kinesins, Prostatic Neoplasms, Disease Progression. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 249 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Prostate cancer causes numerous male deaths annually. Although great progress has been made in the diagnosis and treatment of prostate cancer during the past several decades, much about this disease remains unknown, especially its pathobiology. The kinesin superfamily is a pivotal group of motor proteins, that contains a microtubule-based motor domain and features an adenosine triphosphatase activity and motility characteristics. Large-scale sequencing analyses based on clinical samples and animal models have shown that several members of the kinesin family are dysregulated in prostate cancer. Abnormal expression of kinesins could be linked to uncontrolled cell growth, inhibited apoptosis and increased metastasis ability. Additionally, kinesins may be implicated in chemotherapy resistance and escape immunologic cytotoxicity, which creates a barrier to cancer treatment. Here we cover the recent advances in understanding how kinesins may drive prostate cancer progression and how targeting their function may be a therapeutic strategy. A better understanding of kinesins in prostate cancer tumorigenesis may be pivotal for improving disease outcomes in prostate cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
- Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. Electronic address: lijf@zju.edu.cn.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China. Electronic address: xielp@zju.edu.cn.
Förderung
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
- China Postdoctoral Science Foundation
Zitieren
APA
Wang, J. M., Zhang, F. H., Liu, Z. X., Tang, Y. J., Li, J. F., & Xie, L. P. (2024). Cancer on motors: How kinesins drive prostate cancer progression?. Biochemical Pharmacology, 224, 116229. https://doi.org/10.1016/j.bcp.2024.116229
Vancouver
Wang JM, Zhang FH, Liu ZX, Tang YJ, Li JF, Xie LP. Cancer on motors: How kinesins drive prostate cancer progression?. Biochemical Pharmacology. 2024;224:116229. doi:10.1016/j.bcp.2024.116229
BibTeX
@article{Wang2024,
author = {Wang, Jia-Ming and Zhang, Feng-Hao and Liu, Zi-Xiang and Tang, Yi-Jie and Li, Jiang-Feng and Xie, Li-Ping},
title = {Cancer on motors: How kinesins drive prostate cancer progression?},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {224},
pages = {116229},
doi = {10.1016/j.bcp.2024.116229}
}
EUVIMED